about
Genetic variability of the mTOR pathway and prostate cancer risk in the European Prospective Investigation on Cancer (EPIC).CXCR6 induces prostate cancer progression by the AKT/mammalian target of rapamycin signaling pathway.Exploiting novel molecular targets in gastrointestinal cancers.CXCL16/CXCR6 chemokine signaling mediates breast cancer progression by pERK1/2-dependent mechanisms.In vivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities.Physiologically based pharmacokinetic models for everolimus and sorafenib in mice.The benefit of everolimus in recurrent/epithelioid angiosarcoma patients: Case reports and literature review.
P2860
Q33836807-B9260DA9-6EC6-4837-8193-456D6712A5A1Q33909085-86CFD03B-A9BD-4EB4-A60C-9652BF9E5094Q34382777-F9E7DA0C-3558-4277-B303-11276E0C9FBFQ35987292-0DD4BA20-3CB5-4F1C-8256-08E16D23BD40Q39906054-A3A7CB8E-3F95-46F6-B09A-428983DF8D22Q42575030-18ED2729-B265-4410-9DFD-CE2432CFB8B5Q47155916-DDCA9FAB-ADF1-492A-9C04-95CF9DECC450
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Targeting mTOR for cancer treatment.
@ast
Targeting mTOR for cancer treatment.
@en
Targeting mTOR for cancer treatment.
@nl
type
label
Targeting mTOR for cancer treatment.
@ast
Targeting mTOR for cancer treatment.
@en
Targeting mTOR for cancer treatment.
@nl
prefLabel
Targeting mTOR for cancer treatment.
@ast
Targeting mTOR for cancer treatment.
@en
Targeting mTOR for cancer treatment.
@nl
P1476
Targeting mTOR for cancer treatment
@en
P2093
Belen Rubio-Viqueira
P304
P577
2006-06-01T00:00:00Z